CTOs on the Move

Esker Therapeutics

www.eskertx.com

 
We are a precision medicines company looking to eliminate the “all comer” approach that is seen with today`s treatments for people with autoimmune disease. We are leveraging a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug development and immunology, in order to create medicines that change the lives of people with autoimmune disease.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.eskertx.com
  • 611 Gateway Boulevard Suite 820
    South San Francisco, CA USA 94080
  • Phone: n/a

Executives

Name Title Contact Details

Funding

Esker Therapeutics raised $70M on 05/05/2021

Similar Companies

Professional Imaging Consultants

Professional Imaging Consultants is a Winter Springs, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.

OLIVIAGroup

OLIVIAGroup is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Absci

Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.

Arixa Pharmaceuticals

Arixa Pharmaceuticals™ is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Our lead program is an oral prodrug of Avibactam®, a broad spectrum beta-lactamase inhibitor recently approved by FDA. We have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.